FindMyKOL
Clinical trialNCT02645175TerminatedPhase 2Interventional

Evaluate the Safety Profile and Ability of TW1025 Oral Solution to Decrease Fatigue

NCT02645175 is a phase 2 interventional trial sponsored by Meriyana Bio Inc.. As of 21 Nov 2026, it was terminated. It studies Fatigue and Metastatic Breast Cancer. The registry lists an enrollment of 3 participants. The registry lists a start date of 31 Jan 2016 and a primary completion date of 31 Dec 2018.

SponsorMeriyana Bio Inc.Enrollment3FatigueMetastatic Breast Cancer
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT02645175
FieldValue
Registry IDNCT02645175
StatusTerminated
PhasePhase 2
Study typeInterventional trial
Lead sponsorMeriyana Bio Inc.
Enrollment3
ConditionsFatigue and Metastatic Breast Cancer
Start31 Jan 2016
Primary completion31 Dec 2018
Study completion31 Dec 2018
Last update posted21 Oct 2016

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

A randomized, double-blind, placebo-controlled, parallel study to evaluate the safety profile and ability of TW1025 oral solution to decrease fatigue in HER2-negative metastatic breast cancer patients receiving chemotherapy.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

No facility list is in our current data snapshot for this study. The registry record on ClinicalTrials.gov ↗ carries any published locations. Why? →

Drugs studied

No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Questions about NCT02645175

Each answer restates registry values shown on this page.

What is NCT02645175?

NCT02645175 is a phase 2 interventional trial sponsored by Meriyana Bio Inc.. It studies Fatigue and Metastatic Breast Cancer.

Who leads NCT02645175?

The registry names Anderson Thomas, MD (principal investigator, Texas Oncology-Bedford), Crane Gregory, MD (principal investigator, The University of Kansas Cancer Center), Danso Michael, MD (principal investigator, Virginia Oncology Associates) and 12 more officials as overall officials.

When did NCT02645175 end?

The registry lists a primary completion date of 31 Dec 2018 and a study completion date of 31 Dec 2018. The sponsor last updated the record on 21 Oct 2016.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.